Pharmacology of cannabinoid receptors

Annual Review of Pharmacology and Toxicology

Volumn 35, Issue , 1995, Pages 607-634

  Howlett, Allyn C ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

adenylate cyclase; aminoalkylindoles; analgesics; eicosanoids; G protein coupled receptors

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 [2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL]CYCLOHEXANOL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ADENYLATE CYCLASE; AMINOALKYLINDOLE DERIVATIVE; ANANDAMIDE; CALCIUM CHANNEL; CANNABINOID; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; DEACETYLLEVONANTRADOL; DELTA G TETRAHYDROCANNABINOL; GUANINE NUCLEOTIDE BINDING PROTEIN; HEXAHYDRO 9BETA HYDROXY 9 NORCANNABINOL; ICOSANOID DERIVATIVE; LEVONANTRADOL; PRAVADOLINE; RECEPTOR SUBTYPE; RIMONABANT; UNCLASSIFIED DRUG; WIN 56098;

ANALGESIA; ANIMAL MODEL; BEHAVIOR; BRAIN; COGNITION; ENDOCRINE SYSTEM; HUMAN; LIGAND BINDING; LOCOMOTION; MEMORY; NERVOUS SYSTEM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA; MAMMALIA;

EID: 0028987880     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pa.35.040195.003135     Document Type: Review

References (162)

1. Gaoni Y, Mechoulam R. 1964. Isolation, structure and partial synthesis of an active consument of hashish. J. Am. Chem. Soc. 86:1646-47
2. Abood ME, Martin BR. 1992. Neurobiology of marijuana abuse. Trends Pharmacol. Sci. 13:201-6
3. Dewey WL. 1986. Cannabinoid pharmacology. Pharmacol. Rev. 38:151-78
4. Hollister LE. 1986. Health aspects of cannabis. Pharmacol. Rev. 38:1-20
5. Mechoulam R. 1986. The pharmacohistory of cannabis saliva. In Cannabinoids as Therapeutic Agents, ed. R Mechoulam, pp. 1-20. Boca Raton: CRC Press
6. 9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci. Biobehav. Rev. 16:55-62
7. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, et al. 1991. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem. Behav. 40: 471-78
8. Razdan RK. 1986. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38:75-149
9. Gerard C, Mollereau C, Vassart G, Parmentier M. 1990. Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res. 18:7142
10. Gerard CM, Mollereau C, Vassart G, Parmentier M. 1991. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279:129-34
11. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-64
12. Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
13. Hewlett AC, 1990. Reverse pharmacology applied to the cannabinoid receptor. Trends Pharmacol. Sci. 11:395-97
14. Hewlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, et al. 1990. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 13: 420-23
15. Hewlett AC, Evans DM, Houston DB. 1992. The cannabinoid receptor. See Ref. 162, pp. 35-72
16. Pertwee R. 1993. The evidence for the existence of cannabinoid receptors. Gen. Pharmacol. 24:811-24
17. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, et al. 1993. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214: 173-80
18. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR. 1992. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42:736-42
19. Lynn AB, Herkenham M. 1994. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268:1612-23
20. Martin BR. 1986. Cellular effects of cannabinoids. Pharmacol. Rev. 38:45-74
21. Pertwee RG. 1988. The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther. 36:189-261
22. Howlett AC. 1995. Cannabinoid compounds and signal transaction mechanisms. See Ref. 159. pp. 167-204
23. Makriyannis A, Rapaka RS. 1990. The molecular basis of cannabinoid activity. Life Sci. 47:2173-84
24. 9-tetranydrocannabinol and its relationship to pharmacological potency. J. Pharmacol. Exp. Ther. 255:624-30
25. Edery H, Grunfeld Y, Ben-Zvi Z, Mechoulam K. 1971. Structural requirements for cannabinoid activity. Ann. NY Acad. Sci. 191:40-53
26. Jones G, Pertwee KG, Gill EW, Paton WDM. Nilsson IM, et al. 1974. Relative pharmacological potency in mice of optical isomers of delta-1-tetrahydrocannabinol. J. Med. Chem. 28:783-87
27. Martin BR, Bolster RL, Razdan RK, Harris LS, Dewey WL. 1981. Behavioral comparisons of the stereoisomers of telrahydrocannabinols. Life Sci. 29:565-74
28. Uliss DB. Ualzell HC, Handrick GR, Howes JF, Razdan RK. 1975. Hashish. Importance of the phenolic hydroxyl group in tetrahydrocannabinols. J. Med. Chem. 18:213-15
29. 8-THC-dimelhylheptyl in mice and dogs. Pharmacol. Biochem. Behav. 22:661-66
30. 8-tetrahydrocannabinol-dimethylheptyl to inhibit adeny late cyclase and bind to the cannabinoid receptor. Neuropharmacology 29:161-65
31. Edcry H. Grunfeld Y, Porath G, Ben-Zvi Z, Shani A, el al. 1972. Structure-activity relationships in the tetrahydrocannabinol series. Arneim. Forsch. 22: 1995-2003
32. Loev B. Bender PE, Dowalo F, Macko E, Fowler PJ. 1973. Cannabinoids. Structure-activity studies related to 1,2-dimethylheptyl derivatives. J. Med. Chem. 16:1200-6
33. Mechoulam R, Edery H. 1973. Structure activity relationships in the cannabinoid series. In Marijuana Chemistry. Pharmacology, Metabolism and Clinical Effects. ed. R Mechoulam. pp. 101-36. New York: Academic
34. Gill EW, Pawn WD, Pertwee RG. 1970. Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 228:134-36
35. Hollister LE. 1974. Structure-activity re-lationships in man of cannabis constituents, and homologs and metabolites of d'-tetrahydrocannabinol. Pharmacology 11:3-11
36. Johnson MR, Melvin LS, Althuis TH. Bindra JS, Harbert CA, et al. 1981. Selective and potent analgetics derived from cannabinoids. J. Clin. Pharmacol. 21:8271-82
37. Christensen HO, Freudenthal RI. Gidley JT, Rosenfeld R. Boegli G, et al. 1971. Activity of delta-8-and delta-9-tetrahydrocannabinol and related compounds in the mouse. Science 172:165-67
38. 9-Tetrahydrocannabinol and its metabolites in monkey brains. J. Pharm. Pharmacol. 24:414-16
39. Lemberger L, Silberstein SD, Axclrod J. Kopin U. 1970. Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science 170:1320-22
40. Handrick GR, Duffley RP, Lambert G, Murphy JG, Dalzell HC, et al. 1982. 3′-Hydroxy-and (±)-3′,11-dihydroxydelta-9-tctrahydrocannabinol: biologically active metabolites of delta-9-tetrahydrocannabinol. J. Med. Chem. 25:1447-50
41. Martin BR, Harris LS, Dewey WL. 1984. Pharmacological activity of delta9-THC metabolites and analogs of CBD, delta-8-THC and delta-9-THC. See Ref. 160, pp. 523-44
42. Ohlsson A, Agurell S, Leander K, Dahmen J, Edery H, et al. 1979. Synthesis and psychotropic activity of side-chain hydroxylated delta-6-telrahydrocannabinol metabolites. Acta Pharm. Suec. 16:21-33
43. 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse. Acta Pharmacol. Toxicol. 47:308-17
44. Hewlett AC. 1987. Cannabinoid inhibition of adenylate cyclase: relative activity of constituents and metabolites of marihuana. Neuropharmacology 26: 507-12
45. Compton DR, Martin BR. 1990. Pharmacological evaluation of water soluble cannabinoids and related analogs. Life Sci. 46:1575-85
46. Reggio PH, Greer KV, Cox SM. 1989. The importance of the orientation of the C9 substituent to cannabinoid activity. J. Med. Chem. 32:1630-35
47. Reggio PH, Panu AM, Miles S. 1993. Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach J. Med. Chem. 36:1761-71
48. Hollister LE. 1973. Cannabidiol and cannabinol in man. Experieniia 29:825-26
49. Perez-Reyes M, Timmons MC, Davis KH, Wall ME. 1973. A comparison of the pharmacological activity in man of intravenously administered delta-9-tetrahydrocannabinol, cannabinol, and cannabidiol. Experientia 29:1368-69
50. Jorapur VS, Khalil ZH, Duffley RP, Razdan RK, Martin BR, et al. 1985. Hashish: synthesis and central nervous activity of some novel analogs of cannabidiol and oxepin derivatives of delta9-tetrahydrocannabinol. J. Med. Chem. 28:783-87
51. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:605-13
52. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, et al. 1993. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 265:218-26
53. 1-tetrahydrocannabinol towards the pharmacological activity of 5 1-tetrahydrocannabinol in mice. Biochem. Pharmacol. 22:175-84
54. Lemberger L, Crabtree RE, Rowe HM. 1972. 11-Hydroxy-delta-9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite in man. Science 177:62-63
55. Jarbe TUC, McMillan DE. 1980. Delta9-THC as a discriminative stimulus in rats and pigeons: generalization to THC metabolites and SP-111. Psychopharmacology 71:281-89
56. Watanabe K, Yamamoto I, Oguri K, Yoshimura H. 1980. Comparison in mice of pharmacological effects of delta-8-tetrahydrocannabinol and its metabolites oxidized at the 11-position. Eur. J. Pharmacol. 63:1-6
57. Wilson RS, May EL. 1975. Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J. Med. Chem. 18:700-3
58. Wilson RS, May EL, Martin BR, Dewey WL. 1976. 9-Nor-9-hydroxyhexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols. J. Med. Chem. 19:1165-67
59. Perez-Reyes M, Timmons MC, Lipton MA, Christensen HD, Davis HK, et al. 1973. A comparison of the pharmacological activity of delta-9-tetrahydrocannabinol and its monohydroxylated metabolites in man. Experientia 29: 1009-10
60. 9-tetrahydrocannabinol. Science 177:633-35
61. Grunfeld Y, Edery H. 1969. Psychopharmacological activity of the active constituents of hashish and some related cannabinoids. Psychopharmacologia 14: 200-10
62. Watanabe K, Oguri K, Yoshimura H. 1979. Synthesis of delta-8-tetrahydrocannabinol glucuronide and sulfate and their metabolic disposition in rats. Chem. Pharm. Bull. 27:3009-14
63. Reggio PH, Seltzman HH, Compton DR, Prescott WR, Martin BR. 1990. Investigation of the role of the phenolic hydroxyl in cannabinoid activity. Mol. Pharmacol. 38:854-62
64. Johnson MR, Melvin LS. 1986. The discovery of nonclassical cannabinoid analgetics. See Ref. 5, pp. 121-45
65. Melvin LS, Johnson MR. 1987. Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids. NIDA Res. Monogr. 79:31-47
66. Johnson MR, Melvin LS, Milne GM. 1982. Prototype cannabinoid analgetics, prostaglandins and opiates - a search for points of mechanistic interaction. Life Sci. 31:1703-6
67. Howlett AC, Johnson MR, Melvin LS, Milne GM. 1988. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 33: 297-302
68. Compton DR, Johnson MR, Melvin LS, Martin BR. 1992. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 260:201-9
69. Melvin LS, Milne GM, Johnson MR, Subramaniam B, Wilken GH, et al. 1993. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 44: 1008-15
70. Xie XQ, Yang DP, Melvin LS, Makriyannis A. 1994. Conformational analysis of the prototype nonclassical cannabinoid CP-47,497, using 2D NMR and computer molecular modeling. J. Med. Chem. 37:1418-26
71. Kriwacki RW, Makriyannis A. 1989. The conformational analysis of delta-9-and delta-9,11-telrahydrocannabinols in solution using high resolution nuclear magnetic resonance spectroscopy. Mol. Pharmacol. 35:495-503
72. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. 1988. Pharmacology and stereoselectivity of structurally novel cannahinoids in mice. J. Pharmacol. Exp. Ther. 247:1046-51
73. Bell MR, D'Ambra TE, Kumar V, Kissenstat MA, Herrmann JL, et al. 1991. Antinociceptive (aminoalkyl)-indoles. J. Med. Chem. 34:1099-110
74. D'Ambra TH, Estep KG, Bell MR, Kissenstat MA, Josef KA. et al. 1992 Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J. Med. Chem. 35:124-35
75. Haubrich DR, Ward SJ, Baizman K, Bell MR, Bradford J, et al. 1990. Pharmacology of pravadoline: a new analgesic agent. J. Pharmacol. Exp., Ther. 255: 511-22
76. Ward SJ, Mastriani D, Casiano F, Arnold R. 1990. Pravadoline: profile in isolated tissue preparations. J. Pharmacol. Exp. Ther. 255:1230-39
77. Pacheco M, Childers SR, Arnold R. Casiano F, Ward SJ. 1991. Aminoalkylindoles: actions on specific G-protein-linked receptors. J. Pharmacol Exp. Ther. 257:170-83
78. 8-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 263: 1118-26
79. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA. 1993. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 264:1352-63
80. Ward SJ, Baizman E, Bell M, Childers S, D'Ambra T, et al. 1990 Aminoalkylindoles (AAIs): a new roule to the cannabinoid receptor? NIDA Res. Monogr. 105:425-26
81. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1982.
82. Vogel Z, Barg J, Levy R, Saya D, Heldman E, et al. 1993. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:352-55
83. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, et al. 1993. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA 90:7656-60
84. Pinto JC, Potie F, Rice KC, Bonng D, Johnson MR, et al. 1994. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46:516-22
85. Childers SR, Sexton T, Roy MB. 1994. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:711-15
86. Johnson DE, Heald SL, Dally RD, Janis RA. 1993. Isolation, identification and synthesis of an endogenous arachidonic amide, Prostaglandins Leukot. Essent. Fatty Acids 48:429-37
87. Hanus L, Gopher A, Almog S, Mechoulam R. 1993. Two new iinsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:3032-34
88. Mackie K, Devane WA, Hille B. 1993. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:498-503
89. Deutsch DG, Chin SA. 1993. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:791-96
90. Fride E, Mechoulam R. 1993. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231: 313-14
91. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, et al. 1994. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:219-27
92. Milne GM, Johnson MR. 1981. Levonantradol: a role for central prostanoid mechanisms? J. Clin. Pharmacol 21: S367-74
93. Home WC. 1984. Desacetyl-1-nantradol: a selective prostaglandin antagonist. Prostaglandins Leukot. Med. 15:129-36
94. Bidaut-Russell M, Devane WA, Howlett AC, 1990. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J. Neu. rochem. 55:21-26
95. Evans DM. Johnson MR, Howlett AC. 1992. Ca(2+)-dependent release from rat brain of cannabinoid receptor binding activity. J. Neurochem. 58:780-82
96. Evans DM. Lake JT, Johnson MR, Hewlett AC. 1994. Endogenous cannabinoid receptor binding activity released from rat brain slices by depolarization. J. Pharmacol. Exp. Ther. 268:1271-77
97. Deadwyler SA, Hampson RE, Childers SR. 1994. Functional significance of cannabinoid receptors in brain. See Ref. 159, pp. 205-31
98. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, et al. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:240-44
99. Howlett AC. 1985. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol. Pharmacol. 27:429-36
100. Howlett AC, Fleming RM. 1984. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26:532-38
101. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29: 307-13
102. Devane WA, Spain JW, Coscia CJ, Howlett AC. 1986. An assessment of the role of opioid receptors in the response to cannabimimetic drugs. J. Neurochem. 46:1929-35
103. Selley DE, Breivogel CS, Childers SR. 1993. Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins. Mol. Pharmacol. 44:731-11
104. Pacheco MA, Ward SJ, Childers SR. 1993. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells, Brain Res. 603:102-10
105. Bidaut-Russell M, Howlett AC. 1991. Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum. J. Neurochem. 57:1769-73
106. Houston DB, Howlett AC. 1993. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol. Pharmacol. 43:17-22
107. Childers SR, Pacheco MA, Bennett BA, Edwards TA, Hampson RE, et al. 1994. Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochem. Soc. Symp. 59:27-50108.
108. Deadwyler SA. Hampson RE, Bennett BA, Edwards TA, Mu J, et al. 1993. Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept. Channels 1:121-34
109. Pacheco MA, Ward SJ, Childers SR. 1994. Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes. J. Neurochem. 62:1773-82
110. Caulfield MP, Brown DA. 1992. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106:231-32
111. Mackie K, Hille B. 1992. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA 89:3825-29
112. Harris RA, Stokes JA. 1982. Cannabinoids inhibit calcium uptake by brain synaptosomes. J. Neurosci. 2:443-47
113. Felder CC, Veluz JS, Williams HL, Briley EM, Malsuda LA. 1992. Cannabinoid agonists stimulate both receptor-and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol. Pharmacol. 42: 838-45
114. Mu J, Kirby MT, King VC, Bennett BA, Hampson RE, et al. 1993. Cannabinoids increase potassium A-current and decrease synaptic transmission via cAMP dependent processes in hippocampus. Soc. Neurosci. Abstr. 19:280
115. Schatz AR, Kessler FK, Kaminski NE. 1992. Inhibition of adenylate cyclase by delta-9-tetrahydrocannabinol in mouse spleen cells: a potential mechanism for cannabinoid-mediated immunosuppression. Life Sci. 51:PL25-30
116. Rowley JT, Rowley PT. 1990. Tetrahydrocannabinol inhibits adenyl cyclase in human leukemia cells. Life Sci. 46:217-22
117. Yebra M, Klein TW, Friedman H. 1992. Delta-9-tetrahydrocannabinol suppresses concanavalin A induced increase in cytoplasmic free calcium in mouse thymocytes. Life Sci. 51:151-60
118. Segal M. 1986. Cannabinoids and analgesia. See Ref. 5, pp. 105-20
119. Bloom AS, Dewey WL, Harris LS, Brosius KK. 1977. 9-nor-β-Hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine. J. Pharmacol. Exp. Ther. 200:263-70
120. McIlhenny HM, Mast RW, Johnson MR, Milne GM. 1981. Nantradol hydrochloride: pharmacokinetics and behavioral effects after acute and chronic treatment J. Pharmacol. Exp. Ther. 219:363-69
121. Jain AK, Ryan JR, McMahon FG, Smith G. 1981. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J. Clin. Pharmacol. 21: S320-26
122. Melvin LS, Milne GM, Johnson MR, Wilken GH, Hewlett AC. 1994. Structure-activity relationships for cannabinoid receptor binding and analgesicactivity: studies leading to the development of the ACD-tricyclic cannabinoids. Mol. Pharmacol. Submitted
123. Lichtman AH, Martin BR. 1991. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:517-23
124. Welch SP, Stevens DL. 1992. Antinociceptive activity of imrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262:10-18
125. Yaksh TL. 1981. The antinociceptive effects of intrathecallv administered levonantradol and desacetyl-levonantradol in the rat. J. Clin. Pharmacol. 21:5334-40
126. Welch SP. 1993. Blockade of cannabinoid-mduced antinociception by norbinallorphimine, but not N,N-diallyl-lyrosine-aib-phenylalanine-lcucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265:633-40
127. 9-telrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268: 1381-87
128. Martin WJ, Lai NK, Patrick SL, Tsou PK, Walker JM. 1993. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629:300-4
129. Lichtman AH, Martin BR. 1991. Cannabinoid-induced antinociception is mediated by a spinal alpha-2-noradrenergic mechanism. Brain Res. 559: 309-14
130. Hollister LE, Gillespie UK. 1973, Delta-8-and delta-9-tetrahvdrocannabinol comparison in man by oral and intravenous administration, Clin. Pharmacol. Ther. 14:353-57
131. Chait LD, Pierri J. 1992. Effects of smoked marijuana on human performance: a critical review. See Ref. 162. pp. 387-424
132. Ferram DP. 1980 Acute effects of marijuana on human memory and cognition. In Marijuana Research Findings: 1980, ed. RC Peterson. pp. 98-119. Bethesda: NIDA Res Monogr. Ser
133. Miller LL. 1984. Marijuana: acute effects on human memory. See Ref. 160, pp. 21-46
134. 9-Tetrahydrocannabinol differentially affects sensoryevoked potentials in the rat dentate gyrus. J. Pharmacol. Exp. Ther. 239: 936-40
135. 9-tetrahydrocannabinol on sensory-evoked discharges of granule cells in the dentate gyrus of behaving rats. J. Pharmacol. Exp. Ther. 239:941-45
136. Hampson RE, Foster TC, Deadwyler SA. 1989. Effects of delta-9-tetrahydrocannabinol on sensory evoked hippocampal activity in the rat: principal components analysis and sequential dependency. J. Pharmacol. Exp. Ther. 251: 870-77
137. Heyser CJ, Hampson RE, Deadwyler SA. 1993. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in shortterm memory associated with changes in task specific firing of hippocampal cells. V. Pharmacol. Exp. Ther. 264:294-307
138. Herkenham M, Lynn AB, deCosta BR, Richfield EK. 1991. Neuronal localization of cannahinoid receptors in the basal ganglia of the rat. Brain Res. 547:267-74
139. Herkenham M, Lynn AB, Johnson MR, Melvm LS, deCosta BR, et al. 1991. Characterization and localization of cannahinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:563-83
140. Herkenham M, Lynn AB, Little MD. Johnson MR. Melvin LS, et al. 1990. Cannabinoid receptor localization in brain. Prof. Naff. Acad. Sci. USA 87: 1932-36
141. 9-THC in the rat. Neuropharmacology 17:137-44
142. Moss DE, McMaster SB, Rogers J. 1981. Tetrahydrocannabinol potentiates rcserpine-induced hypokinesia. Pharmacol. Biochem. Behav. 15:779-83
143. Moss DE, Manderscheid PZ, Kobayashi H, Montgomery SP. 1988. Evidence for the nicotinic cholinergic hypothesis of cannabinoid action within the central nervous system: extrapyramidal motor behaviors. In Marijuana: An International Research Report, ed. G Chesher. P Consroe, R Musty, pp. 359-64. Canberra: Aust. Gov. P'ubl. Serv.
144. Pertwee RG, Ross TM. 1991. Drugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 30: 67-71
145. Pertwee RG, Greentree SG. 1988. Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. Neuropharmacology 27: 485-91
146. Pertwee RG, Greentree SG, Swift PA. 1988. Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 27: 1265-70
147. Murphy LL, Steger RW, Bartke A. 1990. Psychoactive and nonpsychoactive cannabinoids and their effects on reproductive neuroendocrine parameters. In Biochemistry and Physiology of Substance Abuse, ed. RR Watson, 2:73-93. Boca Raton: CRC Press
148. Wenger T, Croix D, Tramu G, Leonardelli J. 1992. Effects of delta-9-tetrahydrocannabinol on pregnancy, puberty, and the neuroendocrine system. See Ref. 162, pp. 539-60
149. 9-telrahydrocannabinol on serum thyrotropin levels in the rat. Pharmacol. Biochem. Behav. 20:547-50
150. Dewey WL, Peng TC, Harris LS. 1970. The effect of 1-trans-delta-9-tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. Eur. J. Pharmacol. 12:382-84
151. Kokka N, Garcia YF. 1974. Effects of delta-9-tetrahydrocannabinoI on growth hormone and adrenocorticotrophic hor-mone secretions in rats. Life Sci. 15:329-38
152. Pertwee RG. 1985. Effects of cannabinoids on thermoregulation: a brief review. See Ref. 161, pp. 263-77
153. Hosko MJ, Schmeling WT, Hardman HF. 1984. Delta-9-tetrahydrocannabinol: site of action for autonomic effects. See Ref. 160, pp. 635-48
154. Jones RT. 1985. Cardiovascular effects of cannabinoids. See Ref. 161, pp. 325-34
155. Vincent BJ, McQuiston DJ, Einhorn LH, Nagy CM, Brames MJ. 1983. Review of cannabinoids and their antiemetic effectiveness. Drugs 25(Suppl. 1):52-62
156. Adler MW, Geller EB. 1986. Ocular effects of cannabinoids. See Ref. 5, pp. 51-70
157. 9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can. J. Physiol. Pharmacol. 56: 968-75
158. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. 1992. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br. J. Pharmacol. 105:980-84
159. Pertwee RG, ed. 1995. Cannabinoid Receptors: Molecular Biology and Pharmacology. London: Academic. In press
160. Agurell S, Dewey WL, Willette RE, eds. 1984. The Cannabinoids: Chemical, Pharmacological and Therapeutic Aspects. New York: Academic
161. Harvey DJ, ed. 1985. Marihuana '84. Oxford: IRL Press
162. Murphy L, Bartke A, eds. 1992. Marijuana/Cannabinoids Neurobiology and Neurophysiology. Boca Raton: CRC Press